Discover the Best Stocks and Maximize Your Portfolio:
- See what stocks are receiving strong buy ratings from top-rated analysts.
- Filter, analyze, and streamline your search for investment opportunities with TipRanks’ Stock Screener.
An update from BriaCell Therapeutics ( (TSE:BCT) ) is now available.
BriaCell Therapeutics Corp. announced the successful outcomes of its annual general shareholder meeting, where 36.26% of its common shares were voted. Shareholders approved all proposed resolutions, including the re-appointment of MNP LLP as auditors and the election of directors with high approval ratings, indicating strong shareholder support for the company’s leadership and strategic direction.
More about BriaCell Therapeutics
BriaCell Therapeutics Corp. is a clinical-stage biotechnology company focused on developing novel immunotherapies to transform cancer care.
YTD Price Performance: -50.86%
Average Trading Volume: 7,536
Technical Sentiment Consensus Rating: Buy
Current Market Cap: C$17.59M
Learn more about BCT stock on TipRanks’ Stock Analysis page.
